Dealing with 'Brexit' is the simply the "cost of doing business" according to Eisai's regional head Gary Hendler. …
Eisai's Gary Hendler: Dealing with Brexit 'the cost of doing business'
January 24, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
Arrotex launches newly developed treatment for Australians with common skin conditions on the PBS
June 3, 2025 - - Latest News -
BMS Australia celebrates silver tier employer status at Australian LGBTQ+ Inclusion Awards
June 3, 2025 - - Latest News -
Sandoz calls for reforms to unlock biosimilar savings
June 3, 2025 - - Latest News -
TGA approves Lilly's GLP-1/GIP receptor for obstructive sleep apnoea
June 3, 2025 - - Latest News -
The needed realignment of belief, certainty and scepticism in our decision-making
June 3, 2025 - - Latest News -
Health department admits review of blood arrangements considering defunding products
June 3, 2025 - - Latest News -
New data uncovers our most painful moments as access to treatment expands
June 2, 2025 - - Latest News